Literature DB >> 3180055

Direct relation of DNA lesions in multidrug-resistant human myeloma cells to intracellular doxorubicin concentration.

W T Bellamy1, R T Dorr, W S Dalton, D S Alberts.   

Abstract

Using a human myeloma cell line selected for resistance to doxorubicin (8226/DOX), which expresses the multidrug resistance phenotype, we studied the effects of drug accumulation on DNA damage and cytotoxicity in multidrug-resistant cells. The resistant 8226 subline showed a decrease in [14C]doxorubicin accumulation as compared to the sensitive (8226/S) subline at all time points investigated. DNA alkaline elution techniques were used to examine the formation of single and double strand breaks and DNA-protein cross-links following exposure to doxorubicin in both sensitive and resistant sublines. When 8226/S and 8226/DOX40 cells were exposed to the same extracellular concentration of doxorubicin there was a difference in the quantity of DNA lesions occurring, with the 8226/DOX40 line exhibiting less DNA damage. However, when the extracellular concentration of drug was adjusted to yield equivalent intracellular concentrations these differences were removed and both lines exhibited the same degree of damage for all three DNA lesions. The same DNA lesions were also studied in isolated nuclei from sensitive and resistant cells. Such a model removes any confounding factors due to drug accumulation such as altered cytosolic distribution and/or metabolism of drug. We observed no difference in the formation of single or double strand breaks, or DNA-protein cross-links when the nuclei were exposed to the same concentration of doxorubicin. Results from colony-forming assays have shown that when resistant and sensitive 8226 cells were exposed to high concentrations of doxorubicin, there was a good correlation between DNA damage, drug accumulation, and cytotoxicity. This relationship did not hold for lower concentrations of doxorubicin, for which there was a lack of correlation between drug accumulation and cytotoxicity. Such findings may possibly be due to a prolonged retention of drug by the sensitive cell line as compared to the resistant cells. Further studies are under way to examine this possibility.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3180055

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.

Authors:  Laurence Catley; Ellen Weisberg; Tanyel Kiziltepe; Yu-Tzu Tai; Teru Hideshima; Paola Neri; Pierfrancesco Tassone; Peter Atadja; Dharminder Chauhan; Nikhil C Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

2.  DNA damage and cytotoxicity of mitoxantrone and doxorubicin in doxorubicin-sensitive and -resistant human colon carcinoma cells.

Authors:  L Capolongo; G Belvedere; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  The interaction of Fe(III), adriamycin and daunomycin with nucleotides and DNA and their effects on cell growth of fibroblasts (NIH-3T3).

Authors:  I Di Liegro; A Cestelli; B F Matzanke; E Bill; A X Trautwein
Journal:  Biometals       Date:  1996-04       Impact factor: 2.949

4.  Lack of involvement of reactive oxygen in the cytotoxicity of mitoxantrone, CI941 and ametantrone in MCF-7 cells: comparison with doxorubicin.

Authors:  G R Fisher; L H Patterson
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.

Authors:  Joel G Turner; Jana L Dawson; Steven Grant; Kenneth H Shain; William S Dalton; Yun Dai; Mark Meads; Rachid Baz; Michael Kauffman; Sharon Shacham; Daniel M Sullivan
Journal:  J Hematol Oncol       Date:  2016-08-24       Impact factor: 17.388

6.  Alterations in glutathione levels and apoptotic regulators are associated with acquisition of arsenic trioxide resistance in multiple myeloma.

Authors:  Shannon M Matulis; Alejo A Morales; Lucy Yehiayan; Kelvin P Lee; Yong Cai; Lawrence H Boise
Journal:  PLoS One       Date:  2012-12-21       Impact factor: 3.240

7.  Changes in subcellular doxorubicin distribution and cellular accumulation alone can largely account for doxorubicin resistance in SW-1573 lung cancer and MCF-7 breast cancer multidrug resistant tumour cells.

Authors:  G J Schuurhuis; T H van Heijningen; A Cervantes; H M Pinedo; J H de Lange; H G Keizer; H J Broxterman; J P Baak; J Lankelma
Journal:  Br J Cancer       Date:  1993-11       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.